498 related articles for article (PubMed ID: 30521105)
1. A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma.
Jiang C; Wang H; Xia C; Dong Q; Chen E; Qiu Y; Su Y; Xie H; Zeng L; Kuang J; Ao F; Gong X; Li J; Chen T
Cancer; 2019 Apr; 125(7):1081-1090. PubMed ID: 30521105
[TBL] [Abstract][Full Text] [Related]
2. A Phase II Randomized Clinical Trial and Mechanistic Studies Using Improved Probiotics to Prevent Oral Mucositis Induced by Concurrent Radiotherapy and Chemotherapy in Nasopharyngeal Carcinoma.
Xia C; Jiang C; Li W; Wei J; Hong H; Li J; Feng L; Wei H; Xin H; Chen T
Front Immunol; 2021; 12():618150. PubMed ID: 33841399
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial.
Liang L; Liu Z; Zhu H; Wang H; Wei Y; Ning X; Shi Z; Jiang L; Lin Z; Yan H; Wang R; Hu K
Cancer; 2022 Apr; 128(7):1467-1474. PubMed ID: 34910297
[TBL] [Abstract][Full Text] [Related]
4. Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial.
Yan P; Yin H; Guo W; Sun X; Li F; Huang S; Bian X; Wang F; Zhang F; Wang B; Zhou H; Zhou C; Yin L; Jiang X; Jiang N; Wu J; Liu J; Song D; He X
Cancer Med; 2020 Sep; 9(17):6166-6172. PubMed ID: 32657029
[TBL] [Abstract][Full Text] [Related]
5. Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.
Anderson CM; Lee CM; Saunders DP; Curtis A; Dunlap N; Nangia C; Lee AS; Gordon SM; Kovoor P; Arevalo-Araujo R; Bar-Ad V; Peddada A; Colvett K; Miller D; Jain AK; Wheeler J; Blakaj D; Bonomi M; Agarwala SS; Garg M; Worden F; Holmlund J; Brill JM; Downs M; Sonis ST; Katz S; Buatti JM
J Clin Oncol; 2019 Dec; 37(34):3256-3265. PubMed ID: 31618127
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled Trial of Shuanghua Baihe Tablets to Prevent Oral Mucositis in Patients With Nasopharyngeal Cancer Undergoing Chemoradiation Therapy.
Zheng B; Zhu X; Liu M; Yang Z; Yang L; Lang J; Shi M; Wu G; He X; Chen X; Xi X; Zhao D; Zhu G
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):418-426. PubMed ID: 29353657
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study.
Chen TM; Lin KC; Yuan KS; Chang CL; Chow JM; Wu SY
Radiother Oncol; 2018 Oct; 129(1):23-29. PubMed ID: 29277447
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
10. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
12. Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients.
Orlandi E; Iacovelli NA; Rancati T; Cicchetti A; Bossi P; Pignoli E; Bergamini C; Licitra L; Fallai C; Valdagni R; Cavallo A
Oral Oncol; 2018 Nov; 86():266-272. PubMed ID: 30409311
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Infiltrating T Cell Receptor-Beta Repertoires are Linked to the Risk of Late Chemoradiation-Induced Temporal Lobe Necrosis in Locally Advanced Nasopharyngeal Carcinoma.
Wu L; Chung YL
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):165-176. PubMed ID: 30654091
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
[TBL] [Abstract][Full Text] [Related]
16. Benefits of immunonutrition in patients with head and neck cancer receiving chemoradiation: A phase II randomized, double-blind study.
Dechaphunkul T; Arundon T; Raungkhajon P; Jiratrachu R; Geater SL; Dechaphunkul A
Clin Nutr; 2022 Feb; 41(2):433-440. PubMed ID: 35007812
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma.
Liu YJ; Zhu GP; Guan XY
Oral Oncol; 2012 Jun; 48(6):554-9. PubMed ID: 22289637
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial.
Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
Eur J Cancer; 2017 Apr; 75():150-158. PubMed ID: 28235726
[TBL] [Abstract][Full Text] [Related]
20. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
